"Comparison of the frequency of adverse events requiring interventions determined by telephone follow up in hepatocellular carcinoma patients treated with sorafenib and lenvatinib."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Comparison of the frequency of adverse events requiring interventions determined by telephone follow up in hepatocellular carcinoma patients treated with sorafenib and lenvatinib.

507Background: The REFLECT trial demonstrated that lenvatinib is non-inferior to sorafenib for first-line treatment of unresectable hepatocellular carcinoma (uHCC). However, no comparison of the fr... Click to show full abstract

Keywords: hepatocellular carcinoma; frequency adverse; carcinoma; events requiring; adverse events; comparison frequency

Journal Title: Journal of Clinical Oncology
Year Published: 2020

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended